Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of 2-dose TDV in infants and toddlers
2023-001084-54Phase 3
- Sponsor
- Takeda
- Start
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dengue fever comparing TDV with Placebo (2 arms). Primary endpoint: Number of participants with solicited local injection site adverse events within 7 days after vaccination.
02
Drugs
dengue tetravalent vaccine, live, attenuated
03
Conditions
dengue fever
Beyond the preview
Go deeper on 2023-001084-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-001084-54.